EarningsQ2 2026 Earnings Report
MX:AUNAN Q2 2026 EPS Results
Actual EPS$2.53
Consensus EPS$4.56
Beat/MissMissed by -$2.03
One Year Ago EPS$5.92
MX:AUNAN Q2 2026 Revenue Results
Actual Revenue$6.12B
Expected Revenue$6.18B
Beat/MissMissed by -$52.91M
YoY Revenue Growth+20.64%
Earnings Announcement Details
QuarterQ2 2026
Date08/18/2026
TimeAfter Close
Conference CallTuesday, August 18, 2026
MX:AUNAN Upcoming Earnings
Auna S.A. Class A's next earnings date is estimated for November 25, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:AUNAN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented balanced results: strong top-line growth, substantially improved cash generation and clear operational momentum (notably in Mexico, Peru membership expansion and Colombia's payer diversification) were offset by material near-term margin pressures. Adjusted EBITDA declined (consolidated -9% FX-neutral) due to investments in talent, statutory cost pressures and billing reconciliations in Peru. Management reaffirmed revenue guidance (~12% FX-neutral) and expects sequential EBITDA improvement and further leverage reduction, but open prior-period reconciliations and cost pressures create near-term uncertainty.Company Guidance
Consolidated Revenue Growth
Consolidated revenue increased 9% year-over-year (FX-neutral), driven by volume growth and a higher mix of high-complexity services across Mexico, Peru and Colombia.
Strong Cash Generation and Free Cash Flow
Net cash from operating activities reached PEN 441 million for the first six months (+45% year-over-year) and free cash flow increased 181% year-over-year; cash balance rose 43% since year-end 2025.
Mexico Sequential Recovery and High-Complexity Growth
Mexico showed sequential improvement with surgery volumes up ~6–7% sequentially, oncology volumes and revenues accelerating (management cited large YoY increases including chemotherapy/radiotherapy volumes and oncology revenues up significantly vs prior year), revenues +4% year-over-year and sequential revenue +5%; Mexico adjusted EBITDA rose 3% sequentially.
Peru Revenue and Capacity Strength
Peru revenue grew 8% year-over-year, OncoSalud revenue +11% (driven by price adjustments and improved mix) and membership growth of ~6%; capacity utilization reached 83%.
Colombia Revenue Diversification and Growth
Colombia revenue grew ~13% year-over-year; risk-sharing contracts now represent 24% of Colombia revenue (up from 14% a year ago) covering >3 million lives, private payor revenue grew 17% YoY and intervened payors fell to 12% from 18%.
Operational Utilization Improvements
Platform capacity utilization increased to 66% year-to-date (a 2.3 percentage point YTD increase) with sequential improvement of 2.8 percentage points; Colombia utilization reached 79.2%.
Balance Sheet & Leverage Progress
Leverage improved sequentially to 3.6x (from Q1 2026) supported by cash generation; management expects further improvement toward the medium-term target of ~3x net debt/EBITDA by year-end.
Guidance Reaffirmation
Management reaffirmed full-year 2026 revenue guidance of approximately 12% FX-neutral growth and expects adjusted EBITDA growth toward the low end of the 10%–14% guidance range (excluding Peru billing penalties).
MX:AUNAN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed